Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2020-05-12 Director's Dealing
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-05-12 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the pricing and terms of a convertible note offering, including details about the notes, capped call transactions, and use of proceeds. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. Instead, it is an announcement of a financing event and related agreements. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the financing, not just a brief announcement or reference to another report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2020-05-07 English
10-Q
Interim / Quarterly Report Q1 2020
2020-04-29 English
PRIMARY DOCUMENT
Director's Dealing
2020-04-27 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement and additional materials related to the Annual Meeting of Stockholders. It includes information about the meeting date, proposals to be voted on, director nominees, and voting instructions. It explicitly states it is proxy materials for the Annual Meeting and provides details on how to access the full proxy statement and annual report. The document does not contain the full proxy statement or annual report itself but serves as a notice and overview of proxy materials availability. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 5389 characters, which is consistent with a proxy statement or related materials. Hence, the classification is PSI with high confidence.
2020-04-22 English
DEF 14A
Proxy Solicitation & Information Statement
2020-04-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.